Zealand Pharma Announces Financial Results for the First Half of 2025

Company announcement – No. 18 / 2025

Zealand Pharma Announces Financial Results for the First Half of 2025
Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma.

• Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche’s Pharma Day in September and Zealand Pharma’s Capital Markets Day in December.
• Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and Roche breaking ground this August on new high-volume, high-throughput manufacturing facility dedicated to next-generation obesity medicines.
• Strengthening of leadership team to optimally position Zealand Pharma for future growth, with Utpal Singh as Chief Scientific Officer to drive the next wave of innovation and Steven Johnson as Chief Development Officer to spearhead development and regulatory strategies.

Copenhagen, Denmark, August 14, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the six months ended June 30, 2025, and provided a corporate update.

Zealand Pharma ready for catalyst-rich and exciting chapter from position of strength
Adam Steensberg, President and Chief Executive Officer at Zealand Pharma said:
“I am very satisfied to see our historic and transformative collaboration with Roche on petrelintide off to a strong start and progressing at full speed. Our organizational strength and very solid financial position empower us to unlock the full value potential of petrelintide and to accelerate investments in the next wave of innovation. With petrelintide Phase 2 data and survodutide Phase 3 data in obesity rapidly approaching, we are entering a pivotal new chapter for the company.”

Key financial results for H1 2025